Sulodexide Treatment in Patients With Type 2 Diabetes Mellitus and Intermittent Claudication

Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis

“…Randomization was not necessarily associated with blinding. Blinding, with appropriate masking when needed, was specifically indicated in 11 studies [ 64 , 68 – 70 , 75 , 80 , 89 , 92 , 97 , 99 , 102 ]. Another 13 studies were explicitly defined or implicitly detected as open-label [ 63 , 71 , 72 , 74 , 90 , 91 , 94 – 96 , 98 , 100 , 101 , 104 ].…”

“…Signs of retinopathy were monitored as change in hard exudate severity [ 64 ], hard exudate and hemorrhage frequency [ 62 ], incidence of intraocular hemorrhage after panretinal laser coagulation [ 63 ], and rate of recurrence of retinal vein thrombosis [ 65 ]. Vascular complications were monitored using more homogeneous endpoints: pain-free walking distance [ 67 , 69 , 70 ] and maximal walking distance [ 66 , 67 , 69 , 70 ] in PAD, and rate of and time to re-epithelization for diabetes-associated trophic ulcers [ 68 , 71 , 72 ].…”

“…We identified 45 studies that could provide information on the effect of sulodexide in the prevention and/or management of the complications of diabetes, four on ocular complications [62][63][64][65], seven on PAD or diabetesassociated trophic ulcers [66][67][68][69][70][71][72], and 34 on diabetic nephropathy [45,. Data were retrieved from the original published tables or graphs.…”